PE20221034A1 - Derivados de quinolina como inhibidores de proteina quinasa - Google Patents
Derivados de quinolina como inhibidores de proteina quinasaInfo
- Publication number
- PE20221034A1 PE20221034A1 PE2022000218A PE2022000218A PE20221034A1 PE 20221034 A1 PE20221034 A1 PE 20221034A1 PE 2022000218 A PE2022000218 A PE 2022000218A PE 2022000218 A PE2022000218 A PE 2022000218A PE 20221034 A1 PE20221034 A1 PE 20221034A1
- Authority
- PE
- Peru
- Prior art keywords
- alkynyl
- alkenyl
- options
- alkyl
- kinase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Esta referido a compuestos derivados de quinolina de las Formulas IIa a IXa, en donde: R1, R2 son H, halo, alquilo, alquenilo, entre otras opciones; R3 es H, halo, alquinilo, cicloalquilo, entre otras opciones; R4, R'4 son H, CF3, alquilo, alquenilo, alquinilo, cicloalquilo, entre otras opciones; Ra1 es H, alquilo, alquenilo, alquinilo; Ra2 es alquilo, alquenilo, alquinilo, cicloalquilo, entre otras opciones; Ra3 es alquilo, alquenilo, alquinilo, heterociclilo, entre otras opciones; Ra4 es alquilo, alquenilo, alquinilo, heterociclilo, entre otras opciones; T es CH2, NR, O, S; U es C-halo, CR, N; B es CR, O, N, S, NR7'; E es CR, O, N, S, NR7'; D es C, CR, N; m es un numero entre 1 y 2; n es un numero entre 0 y 1; p es un numero entre 0 y 4; q es un numero entre 0 y 2; r es un numero entre 0 y 3; n1 es un numero entre 0 y 5; n2 es un numero entre 0 y 4; n3 es un numero entre 0 y 2; n4 es un numero entre 0 y 4; y x es un numero entre 0 y 7. Estos compuestos son inhibidores de quinasa y son empleados en el tratamiento de diversas enfermedades como cancer, trastornos metabolicos (diabetes), trastornos inflamatorios y autoinmunes (enfermedad de Crohn, colitis ulcerosa, artritis reumatoide, entre otras), trastornos neurologicos (enfermedad de Alzheimer, enfermedad de Parkinson, esclerosis multiple), aterosclerosis, entre otras.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19190898 | 2019-08-08 | ||
PCT/EP2020/072322 WO2021023888A1 (en) | 2019-08-08 | 2020-08-07 | Isoquinoline derivatives as protein kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20221034A1 true PE20221034A1 (es) | 2022-06-17 |
Family
ID=67658619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2022000218A PE20221034A1 (es) | 2019-08-08 | 2020-08-07 | Derivados de quinolina como inhibidores de proteina quinasa |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220388979A1 (es) |
EP (1) | EP4010330A1 (es) |
JP (1) | JP2022548820A (es) |
KR (1) | KR20220066258A (es) |
CN (1) | CN114391009A (es) |
AU (1) | AU2020324561A1 (es) |
BR (1) | BR112022002222A2 (es) |
CA (1) | CA3149846A1 (es) |
CL (1) | CL2022000298A1 (es) |
CO (1) | CO2022001860A2 (es) |
IL (1) | IL290314A (es) |
MX (1) | MX2022001467A (es) |
PE (1) | PE20221034A1 (es) |
WO (1) | WO2021023888A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3216785A1 (en) * | 2021-04-30 | 2022-11-03 | Chengdu Anticancer Bioscience, Ltd. | Phenyl -o-quinoline, quinazoline, thienopyridine, thienopyrimidine, pyrrolopyridine, pyrrolopyrimidine compounds having anticancer activity |
WO2024110608A1 (en) * | 2022-11-24 | 2024-05-30 | Neuralis | Pyridine derivatives as protein kinase inhibitors |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4843066A (en) | 1986-11-27 | 1989-06-27 | Nippon Zoki Pharmaceutical Co., Ltd. | Novel adenosine derivatives and pharmaceutical composition containing them as an active ingredient |
US5674998A (en) | 1989-09-15 | 1997-10-07 | Gensia Inc. | C-4' modified adenosine kinase inhibitors |
US6258793B1 (en) | 1999-12-03 | 2001-07-10 | Cv Therapeutics, Inc. | N6 heterocyclic 5′ modified adenosine derivatives |
WO2003104482A1 (en) | 2002-06-05 | 2003-12-18 | Metabolic Engineering Laboratories Co., Ltd. | Signals and molecular species involved in senescence |
AU2002951247A0 (en) | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
US20050250789A1 (en) | 2004-04-20 | 2005-11-10 | Burns David M | Hydroxamic acid derivatives as metalloprotease inhibitors |
JO2787B1 (en) * | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
US7951819B2 (en) | 2006-04-26 | 2011-05-31 | Cancer Research Technology Limited | Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B] pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds |
BRPI0821227A2 (pt) | 2007-12-19 | 2015-06-16 | Cancer Rec Tech Ltd | Composto, composição farmacêutica, método para preparar a mesma, uso de um composto, método para tratar uma doença ou distúrbio, para inibir função de raf e para inibir proliferação celular, inibir progressão do ciclo celular, promover apoptose, ou uma combinação de um ou mais dos mesmos |
US20110229469A1 (en) * | 2008-10-01 | 2011-09-22 | Ludwig Institute For Cancer Research | Methods for the treatment of cancer |
US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
PL2707359T3 (pl) * | 2011-05-12 | 2017-05-31 | Nerviano Medical Sciences S.R.L. | Podstawione pochodne indazolowe aktywne jako inhibitory kinaz |
JP6617155B6 (ja) * | 2015-04-07 | 2020-01-22 | グアンドン・レイノーヴェント・バイオテック・カンパニー・リミテッド | チロシンキナーゼ阻害剤およびそれを含む医薬組成物 |
WO2017049462A1 (zh) * | 2015-09-22 | 2017-03-30 | 合肥中科普瑞昇生物医药科技有限公司 | 一类新型的flt3激酶抑制剂及其用途 |
-
2020
- 2020-08-07 US US17/633,110 patent/US20220388979A1/en active Pending
- 2020-08-07 WO PCT/EP2020/072322 patent/WO2021023888A1/en active Application Filing
- 2020-08-07 BR BR112022002222A patent/BR112022002222A2/pt unknown
- 2020-08-07 KR KR1020227006134A patent/KR20220066258A/ko unknown
- 2020-08-07 EP EP20751164.3A patent/EP4010330A1/en active Pending
- 2020-08-07 PE PE2022000218A patent/PE20221034A1/es unknown
- 2020-08-07 CN CN202080064561.1A patent/CN114391009A/zh active Pending
- 2020-08-07 MX MX2022001467A patent/MX2022001467A/es unknown
- 2020-08-07 AU AU2020324561A patent/AU2020324561A1/en active Pending
- 2020-08-07 JP JP2022507636A patent/JP2022548820A/ja active Pending
- 2020-08-07 CA CA3149846A patent/CA3149846A1/en active Pending
-
2022
- 2022-02-02 IL IL290314A patent/IL290314A/en unknown
- 2022-02-04 CL CL2022000298A patent/CL2022000298A1/es unknown
- 2022-02-22 CO CONC2022/0001860A patent/CO2022001860A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4010330A1 (en) | 2022-06-15 |
KR20220066258A (ko) | 2022-05-24 |
CL2022000298A1 (es) | 2022-11-25 |
WO2021023888A1 (en) | 2021-02-11 |
CN114391009A (zh) | 2022-04-22 |
WO2021023888A8 (en) | 2021-12-09 |
CA3149846A1 (en) | 2021-02-11 |
AU2020324561A1 (en) | 2022-03-17 |
MX2022001467A (es) | 2022-05-06 |
IL290314A (en) | 2022-04-01 |
JP2022548820A (ja) | 2022-11-22 |
CO2022001860A2 (es) | 2022-06-10 |
BR112022002222A2 (pt) | 2022-06-07 |
US20220388979A1 (en) | 2022-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20221034A1 (es) | Derivados de quinolina como inhibidores de proteina quinasa | |
PE20161443A1 (es) | Compuestos | |
AR040765A1 (es) | Acidos tienil-hidroxamicos sustituidos y su uso para preparar medicamentos y tratar enfermedades asociadas con la acatividad enzimatica de la histona desacetilasa | |
PE20151144A1 (es) | Moduladores de la orphan receptor gamma retinoides relacionados (ror - gamma) para uso en el tratamiento de las enfermedades autoinmunes e inflamatorias | |
PE20210406A1 (es) | Inhibidores de inflamasoma nlrp3 | |
PE20190409A1 (es) | Compuesto heterociclico | |
CO2018013635A2 (es) | Nuevos compuestos como inhibidores de autotaxina y composiciones farmacéuticas que comprenden a los mismos | |
PE20121276A1 (es) | Compuestos espirociclicos que contienen nitrogeno y su uso medicinal | |
AR104784A1 (es) | Péptidos de cadena corta como agonistas de los receptores opioides kappa (k) o kor | |
PE20161292A1 (es) | Compuestos de nicotinamida sustituida con heteroarilo | |
PE20180050A1 (es) | Heterociclos biciclicos como inhibidores de fgfr 4 | |
PE20181074A1 (es) | Compuestos heteroaromaticos como inhibidores de btk | |
PE20212247A1 (es) | Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos | |
MX2019008690A (es) | Compuestos espiro heterociclicos como inhibidores de magl. | |
PE20141973A1 (es) | Compuestos de heterociclilo como inhibidores de mek | |
PE20211049A1 (es) | Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 | |
CO2017011093A2 (es) | Derivados de 6,7-dihidropirido [2,1-a]isoquinolin-2-ona como antagonistas del receptor gpr84, y composiciones que los contienen | |
PH12018500251A1 (en) | Novel compounds as ror gamma modulators | |
ECSP20061378A (es) | COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-gamma | |
AR100818A1 (es) | N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida | |
CO2018009876A2 (es) | Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de fibrosis | |
CL2018002089A1 (es) | Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso | |
PE20161444A1 (es) | 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina | |
PH12018501434A1 (en) | Cyclic amine derivative and medical use thereof | |
PE20190339A1 (es) | 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1 |